Device Trial Radar · NCT04056715
Extended ECG Monitoring in HCM Patients
Last checked: Nov 20, 2026Latest source record: Mar 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
250
Actual
Start
Jan 14, 2020
Primary completion
Apr 18, 2022
Study completion Apr 18, 2022
Sponsor
- Lead sponsor
- iRhythm Technologies, Inc.Public (IRTC)
- Sponsor type
- Industry
- First posted
- Aug 14, 2019
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine, among a large cohort of 300 consecutive patients with hypertrophic cardiomyopathy, if extended ambulatory monitoring using the iRhythm Technologies, Inc. Zio XT device results in identifying a greater burden of nonsustained ventricular tachyarrhythmia (nsVT) compared to current ACCF/AHA guideline recommended 48-hour monitoring.
Conditions
- Hypertrophic Cardiomyopathy
- Nonsustained Ventricular Tachycardia
- Ventricular Tachycardia
- Atrial Fibrillation
- Arrhythmia
Interventions
Zio XTDevice
ambulatory cardiac monitoring device
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total number of nsVT runs through 14 days of ambulatory cardiac monitoring, as compared to the first 48 hours.Time frame: 14 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tufts Medical Center
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.